Abstract
Introduction: The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). Materials and Methods: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. Results: Three international guidelines were evaluated—those developed by the National Comprehensive Cancer Network (2014), the European Society of Medical Oncology (2011) and the European Association of Urology (2013). Recommendations on the use of neoadjuvant and adjuvant chemotherapy in MIBC were developed. Conclusion: These adapted guidelines form the SCAN Guidelines 2015 for neoadjuvant and adjuvant chemotherapy in MIBC.
Key words: Perioperative, Recommendations, Survival benefit
Publisher
Academy of Medicine, Singapore
Reference23 articles.
1. Health Promotion Board, Singapore. Singapore Cancer Registry Report No. 7. Trends in Cancer Incidence in Singapore 1968-2007. Singapore, National Registry of Diseases Office, 2010.
2. Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer 2014;120:1630-8.
3. Fervers B, Burgers JS, Haugh MC, Latreille J, Mlika-Cabanne N, Paquet L, et al. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. Int J Qual Health Care 2006;18:167-76.
4. NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer Version 2.2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf). Accessed on 1 July 2014.
5. Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V; ESMO Guidelines Working Group. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22: vi45-9.